Literature DB >> 9285315

Influence of intraperitoneal vancomycin on peritoneal dialysis efficiency. A clinical study.

L Janicka1, A Ksiazek, J Solski, K Janicki.   

Abstract

Peritonitis is a major complication of intermittent peritoneal dialysis (IPD); over 70% of the infections are caused by Gram-positive bacteria. Vancomycin (V) is the antibiotic of choice in the treatment of peritonitis caused by G(+). The influence of vancomycin on peritoneal transport in IPD patients has not been described before. We have investigated the effect of intraperitoneal vancomycin on dialysis efficiency in 8 IPD patients using dialysis solutions containing either lactate or acetate. The following parameters were measured: net ultrafiltration (UF), concentration ratios (D/P) of urea, creatinine, potassium, peritoneal clearances (ml/min) of urea, creatinine, potassium, mass transfer of sodium (MTNa), sodium sieving index (SCNa). It has been found that vancomycin significantly decreases D/P urea (p < 0.05) and creatinine (p < 0.05). We found also a significant decrease of mean clearance of urea (p < 0.05) and creatinine (p < 0.05). The mean clearance of potassium did not change significantly. There was no significant change in UF, MTNa, and SCNa. Our preliminary data suggest that vancomycin decreases the permeability of peritoneum for certain low molecules in IPD patients which may have a negative impact on dialysis efficiency.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9285315     DOI: 10.1007/bf02550940

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  7 in total

1.  Laboratory diagnosis of peritonitis in patients on continuous ambulatory peritoneal dialysis.

Authors:  H A Ludlam; T N Price; A J Berry; I Phillips
Journal:  J Clin Microbiol       Date:  1988-09       Impact factor: 5.948

2.  Peritoneal dialysis-related peritonitis treatment recommendations. 1993 update. The Ad Hoc Advisory Committee on Peritonitis Management. International Society for Peritoneal Dialysis.

Authors:  W F Keane; E D Everett; T A Golper; R Gokal; C Halstenson; Y Kawaguchi; M Riella; S Vas; H A Verbrugh
Journal:  Perit Dial Int       Date:  1993       Impact factor: 1.756

3.  Changes in peritoneal transport following the use of intraperitoneal gentamicin.

Authors:  L Janicka; M Majdan; J Solski; E Baranowska
Journal:  Perit Dial Int       Date:  1994       Impact factor: 1.756

4.  Staph aureus peritonitis in patients on continuous ambulatory peritoneal dialysis.

Authors:  D Kim; J Tapson; G Wu; R Khanna; S I Vas; D G Oreopoulos
Journal:  Trans Am Soc Artif Intern Organs       Date:  1984

5.  An experimental model for study of pharmacologic and hormonal influences on peritoneal dialysis.

Authors:  J F Maher; P Hirszel; M Lasrich
Journal:  Contrib Nephrol       Date:  1979       Impact factor: 1.580

6.  Peritonitis in continuous ambulatory peritoneal dialysis. Laboratory and clinical studies.

Authors:  R Gokal; J M Ramos; D M Francis; R E Ferner; T H Goodship; G Proud; A J Bint; M K Ward; D N Kerr
Journal:  Lancet       Date:  1982-12-18       Impact factor: 79.321

7.  A five-year study of the microbiologic results of exit site infections and peritonitis in continuous ambulatory peritoneal dialysis.

Authors:  B Piraino; J Bernardini; M Sorkin
Journal:  Am J Kidney Dis       Date:  1987-10       Impact factor: 8.860

  7 in total
  1 in total

Review 1.  Listeria monocytogenes peritonitis in a patient on peritoneal dialysis: a case report and review of the literature.

Authors:  Mufazzal Ahmad; Abirami Krishnan; Elizabeth Kelman; Vanessa Allen; Joanne M Bargman
Journal:  Int Urol Nephrol       Date:  2008-06-19       Impact factor: 2.370

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.